In short
This article discusses a clinical trial investigating the long-term safety and effectiveness of MB-CART20.1, a promising CAR T-cell therapy for patients with advanced B-cell malignancies. The study aims to evaluate potential late-onset side effects, monitor patient outcomes, and assess the persistence of the treatment in patients who have received this innovative therapy.
At a glance
- Study Drug
- MB-CART20.1 (CD20 CAR transduced T cells)
- Target Conditions
- Relapsed or refractory CD20 positive B-cell non-Hodgkin's lymphoma (NHL), B-cell malignancies
- Main Objective
- Evaluate long-term safety after treatment with Miltenyi CAR T cell therapy
- Key Inclusion Criteria
- Treatment with Miltenyi CAR T cell therapy at least 12 months prior to enrollment
- Primary Endpoint
- Percentage of patients with late-onset adverse reactions, serious adverse events, and events of special interest
- Secondary Endpoints
- B- and T-lymphocyte count, growth monitoring in pediatric patients, detection of replication-competent lentivirus, relapse/progression rates, transgene persistence
What is MB-CART20.1?
MB-CART20.1 is an innovative medical treatment classified as a cell and gene therapy. It is specifically designed to treat certain types of blood cancers, particularly B-cell non-Hodgkin's lymphoma (NHL) that have not responded well to other treatments or have come back after previous treatments.
This therapy is also known by other names, including:
- CD20 CAR transduced T cells: This name describes how the treatment works, which we'll explain in more detail below.
- Miltenyi CAR T cell therapy: This refers to the company developing the treatment, Miltenyi Biomedicine GmbH.
How Does MB-CART20.1 Work?
MB-CART20.1 is a type of treatment called CAR T-cell therapy. Here's a simplified explanation of how it works:
- Cell collection: First, some of your own T-cells (a type of immune cell) are collected through a process called leukapheresis.
- Genetic modification: These T-cells are then genetically modified in a laboratory to produce special receptors on their surface called Chimeric Antigen Receptors (CARs).
- Cell multiplication: The modified cells are grown in large numbers in the lab.
- Infusion: The CAR T-cells are then given back to you through an intravenous infusion (a drip into your vein).
- Targeting cancer cells: Once in your body, these modified T-cells can recognize and attack cancer cells that have a specific protein (CD20) on their surface.
The "20" in MB-CART20.1 refers to CD20, which is the specific protein on B-cell lymphoma cells that this therapy targets.
Medical Conditions Treated
MB-CART20.1 is being studied for the treatment of:
- Relapsed or refractory CD20 positive B-cell non-Hodgkin's lymphoma (NHL): This means NHL that has either come back after treatment (relapsed) or didn't respond well to previous treatments (refractory).
It's important to note that this therapy is specifically for lymphomas that are "CD20 positive," meaning the cancer cells have the CD20 protein on their surface.
Clinical Trial Overview
MB-CART20.1 is currently being studied in a clinical trial. This trial is a long-term follow-up study designed to gather more information about the safety and effectiveness of this treatment over time.
The main goals of this study are:
- To evaluate the long-term safety of MB-CART20.1
- To assess how well the treatment continues to work over time
- To monitor for any late-onset side effects
- To check if the modified T-cells persist in the body
Eligibility Criteria
To participate in this long-term follow-up study, patients must meet the following criteria:
- Have received treatment with MB-CART20.1 at least 12 months before enrolling in the long-term follow-up
- Provide informed consent to participate in the study
There are no specific exclusion criteria for this long-term follow-up trial.
Safety and Efficacy Monitoring
During the long-term follow-up, researchers will be closely monitoring several aspects of patients' health and the treatment's effectiveness:
- Safety monitoring: This includes tracking any late-onset side effects, serious adverse events, life-threatening infections, and the development of new or secondary cancers.
- Blood cell counts: Regular checks of B-cell and T-cell counts will be performed.
- Treatment effectiveness: Researchers will monitor how many patients experience a relapse or progression of their disease, and track survival rates over time.
- Persistence of modified cells: Tests will be done to check if the CAR T-cells are still present and active in the body.
- Virus checks: Patients will be monitored for the presence of replication-competent lentivirus, which is related to the method used to modify the T-cells.
For pediatric patients, additional monitoring will include tracking height, weight, and developmental milestones.
This long-term follow-up study is crucial for understanding the full potential and any long-term effects of MB-CART20.1, helping to ensure its safe and effective use in treating B-cell non-Hodgkin's lymphoma.